派格生物医药-B(02565)拟于8月25日召开董事会审议2026年中期业绩

公告速递
Aug 13

派格生物医药(杭州)股份有限公司(02565)8月13日公告,公司董事会将于2026年8月25日(星期二)召开会议,主要议程包括:

1. 审议及批准本集团截至2026年6月30日止六个月的中期业绩及其刊发; 2. 处理任何其他事项。

董事长、执行董事兼总经理Michael Min Xu将在会上主持相关事宜。除其本人外,董事会成员还包括执行董事王小军,非执行董事Xiangjun Zhou、徐宇虹、翟婷、李宏凯,以及独立非执行董事Jiancun Zhang、陈秧秧、廖亦琳。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10